Treating patients suffering from the deadliest form of skin cancer with a combination of drugs could help extend their lives, research has suggested.
Data presented at the European Society for Medical Oncology (ESMO) Congress in Madrid showed that treating patients suffering from advanced melanoma with both cobimetinib and vemurafenib could prevent their disease from progressing for up to 9.9 months.
That could help sufferers live longer, with those being treated with vemurafenib alone seeing their disease halted for 6.2 months.
The new treatment has been trialled on patients from 11 centres across the UK, including the Beatson West of Scotland Cancer Centre in Glasgow and Edinburgh's Western General Hospital.
Advanced melanoma is the most aggressive form of skin cancer, with patients in most cases having a life expectancy of less than a year.
The number of people in Scotland diagnosed with the disease has more than doubled in 24 years, going from 506 cases in 1988 to 1,177 in 2012.
While vemurafenib tablets can potentially reduce tumour size, taking the drug in combination with cobimetinib can enhance anti-tumour activity in the body and delay patients becoming resistant to treatment, according to the drug company Roche.
Dr James Larkin, consultant medical oncologist at The Royal Marsden in London and lead investigator for the trial, said: "We are delighted to have been able to further explore the treatment options for patients with advanced melanoma.
"This data could represent a significant step forward in the treatment of this disease.
"The data shows that the combination of vemurafenib with cobimetinib prolongs progression-free survival significantly in comparison with vemurafenib alone.
"Not only that but it also shows that the side effects are generally manageable, which is incredibly important for our patients.
"Vemurafenib has been hailed as one of the biggest breakthrough treatments for malignant melanoma in the past 30 years and in just three years we have been able to make major strides in improving on its effectiveness as a treatment for patients.
"This latest trial is helping to cement The Royal Marsden as a global leader in this field of research."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article